Mitigating prolonged QT interval in cancer nanodrug development for accelerated clinical translation
Amalendu P Ranjan, Anindita Mukerjee, Lawrence Helson
1Department of Molecular Biology & Immunology and Institute for Cancer Research, Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, Texas 76107, USA. jamboor.vishwanatha@unthsc.edu.
Background:
Cardiac toxicity is the foremost reason for drug discontinuation from development to clinical evaluation and post market surveillance [Fung 35:293-317, 2001; Piccini 158:317-326 2009]. The Food and Drug Administration (FDA) has rejected many potential pharmaceutical agents due to QT prolongation effects. Since drug development and FDA approval takes an enormous amount of time, money and effort with high failure rates, there is an increased focus on rescuing drugs that cause QT prolongation. If these otherwise safe and potent drugs were formulated in a unique way so as to mitigate the QT prolongation associated with them, these potent drugs may get FDA approval for clinical use. Rescuing these compounds not only benefit the patients who need them but also require much less time and money thus leading to faster clinical translation. In this study, we chose curcumin as our drug of choice since it has been shown to posses anti-tumor properties against various cancers with limited toxicity. The major limitations with this pharmacologically active drug are (a) its ability to prolong QT by inhibiting the hERG channel and (b) its low bioavailability. In our previous studies, we found that lipids have protective actions against hERG channel inhibition and therefore QT prolongation.
Results:
Results of the manual patch clamp assay of HEK 293 cells clearly illustrated that our hybrid nanocurcumin formulation prevented the curcumin induced inhibition of hERG K+ channel at concentrations higher than the therapeutic concentrations of curcumin. Comparing the percent inhibition, the hybrid nanocurcumin limited inhibition to 24.8% at a high curcumin equivalent concentration of 18 μM. Liposomal curcumin could only decrease this inhibition upto 30% only at lower curcumin concentration of 6 μM but not at 18 μM concentration.
Conclusions:
Here we show a curcumin encapsulated lipopolymeric hybrid nanoparticle formulation which could protect against QT prolongation and also render increased bioavailability and stability thereby overcoming the limitations associated with curcumin.
Insights
A novel hybrid nanocurcumin formulation effectively prevents drug-induced QT prolongation by protecting the hERG channel. This innovation enhances curcumin
Area of Science:
- Pharmacology
- Nanotechnology
- Drug Development
Background:
- Cardiac toxicity, specifically QT prolongation, is a major cause of drug failure.
- Curcumin, an anti-tumor agent, is limited by QT prolongation and low bioavailability.
- Lipid-based formulations may mitigate hERG channel inhibition and QT prolongation.
Purpose of the Study:
- To develop a novel formulation of curcumin to overcome its limitations.
- To assess the efficacy of a hybrid nanocurcumin formulation in preventing QT prolongation.
- To improve curcumin's bioavailability and stability.
Main Methods:
- Manual patch clamp assay using HEK 293 cells.
- Evaluation of a lipopolymeric hybrid nanoparticle formulation encapsulating curcumin.
- Comparison with liposomal curcumin formulation.
Main Results:
- Hybrid nanocurcumin prevented hERG channel inhibition at therapeutic concentrations.
- Hybrid nanocurcumin limited inhibition to 24.8% at 18 μM curcumin.
- Liposomal curcumin showed limited efficacy at higher concentrations.
Conclusions:
- A lipopolymeric hybrid nanoparticle formulation of curcumin successfully protects against QT prolongation.
- The formulation enhances curcumin's bioavailability and stability.
- This approach offers a strategy to rescue potent drugs with QT prolongation liabilities.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs that Stabilize Microtubules
